Navigation Links
NIH study finds Avastin and Lucentis are equally effective in treating AMD
Date:4/28/2011

Change in visual acuity served as the primary outcome measure for CATT. Thus far, visual acuity improvement was virtually identical (within one letter difference on an eye chart) for either drug when given monthly. In addition, no difference was found in the percentage of patients who had an important gain or loss in visual function. Also, when each drug was given on a PRN schedule, there also was no difference (within one letter) between drugs. PRN dosing required four to five fewer injections per year than monthly treatment. Visual gains were about two letters less with PRN than with monthly treatment but overall visual results were still excellent.

"In addition to the primary finding of equivalence between Lucentis and Avastin for visual acuity, CATT also demonstrates that PRN dosing is a viable treatment option for either of these drugs," said Daniel F. Martin M.D., study chair for CATT and chairman of the Cole Eye Institute at the Cleveland Clinic. "Substantial visual acuity gains may be accomplished with a lower treatment burden."

Adverse events indicate development or worsening of a medical condition. They may or may not be causally associated with the clinical trial treatment, but they are always monitored and reported in any clinical trial. The median age of patients in CATT was over 80 years, and a high rate of hospitalizations might be anticipated as a result of chronic or acute medical conditions more common to older populations.

Serious adverse events (primarily hospitalizations) occurred at a 24 percent rate for patients receiving Avastin and a 19 percent rate for patients receiving Lucentis. These events were distributed across many different conditions, most of which were not associated with Avastin in cancer clinical trials where the drug was administered at 500 times the dose used for AMD. The number of deaths, heart attacks, and strokes were low and similar for both drugs during the study. CATT was not c
'/>"/>

Contact: Jean Horrigan
jh@nei.nih.gov
301-496-5248
NIH/National Eye Institute
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Study targets treatment for serious ACE inhibitor side effect
2. JAMA study reports on fatty liver disease in children and teens
3. Armadillos Give Leprosy to Humans in Southern U.S.: Study
4. Study Highlights Arthritis Toll on Quality of Life
5. Morning Heart Attacks Cause More Damage, Study Finds
6. Higher Oxygen Levels Improve Preemie Survival: Study
7. Baycrest and NHL Alumni partner on brain health study
8. Removing Ovaries During Hysterectomy Wont Raise Other Health Risks: Study
9. University of Houston wins NIH grant for vaccine study
10. When Docs Own MRIs, Back Pain Scans Increase: Study
11. Evidence-Based Heart Attack Care Reduces Deaths: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... the most common type of lung cancer, researchers have ... role in forming tumors. The new knowledge may expand ... genetic changes already are available or are in clinical ... investigators from The Cancer Genome Atlas (TCGA), including researchers ... Harvard Medical School and other institutions, studied tumors from ...
(Date:7/9/2014)... users in Russia might contribute to HIV transmission ... by researchers from Boston University Schools of Medicine ... Pavlov State University, sought to discover the effect ... a cohort of HIV-positive people with lifetime of ... by police were more likely to share needlesincreasing ...
(Date:7/9/2014)... July 9, 2014 There has been a ... UT Southwestern Medical Center using MyChart, the online, interactive ... results, communicate with their healthcare providers, schedule appointments, and ... of patients actively using MyChart each year ... year increased more than 10-fold, according to a study ...
(Date:7/9/2014)... reputation for being highly toxic, but when used in the ... to offer potential health benefits in a range of issues, ... compound (AP39), designed and made at the University of Exeter, ... of very small amounts of the substance to the right ... have already found that the compound protects mitochondria the ...
(Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
Breaking Medicine News(10 mins):Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... a way to predict whether women with ductal carcinoma in ... cancer are at risk of developing more invasive tumors ... women with DCIS will have the opportunity to be more ... will have much more information, so they can better know ...
... for Radiation Oncology (ASTRO) has released its Emerging ... body radiotherapy (SBRT) in lung cancer treatment. SBRT ... focused radiation beams to target a well-defined tumor ... planning and precise treatment setup to deliver the ...
... release is available in French . , Ottawa, ... ideas amongst researchers is a fundamental element in turning knowledge ... Thanks to the newly launched PubMed Central Canada (PMC Canada), ... archive of published Canadian health research. PMC Canada ...
... researchers find , WEDNESDAY, April 28 (HealthDay News) -- ... lung disease caused by cystic fibrosis: Which comes first, ... beginning to answer that question, and it looks like ... an assistant professor of internal medicine at the University ...
... ... Air” in HuffPost Living , ... (PRWEB) April 28, 2010 -- Huffington Post blogger and radio host Kathleen ... radio program, The Kathleen Show ., , ,Each week in The Huffington Post ...
... ... , ... 2010 -- AstraZeneca has agreed to pay $520 million in civil fines, penalties and ... care programs in connection with its marketing and promotional practices for the blockbuster atypical ...
Cached Medicine News:Health News:Breakthrough method predicts risk of invasive breast cancer 2Health News:Breakthrough method predicts risk of invasive breast cancer 3Health News:Canada joins international network providing free access to health research 2Health News:Pigs Yield Clues to Cystic Fibrosis-Related Lung Disease 2Health News:The Kathleen Show Launches Weekly Audio Blog on The Huffington Post 2Health News:AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims 2Health News:AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims 3
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
(Date:1/14/2014)... 14, 2014   NuAire , a manufacturer of ergonomically designed ... Hitachi Koki of Japan to sell ... America . NuAire will utilize its network of sales professionals ... Canada to offer assistance in application use, product benefits ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... 2011 Hill-Rom Holdings, Inc. (NYSE: HRC ) ... January 26, 2011.  The company will host a webcast the ... EST. Earnings Release:   Hill-Rom,s Fiscal 2011 ... 2010, will be issued to the public after the close ...
... Amarin Corporation plc (Nasdaq: AMRN ) (the "Company"), ... today announced that it has completed its previously announced underwritten ... to the public of $7.60 per ADS. Due ... the company sold a total of 13,800,000 ADSs in the ...
Cached Medicine Technology:Hill-Rom Holdings, Inc. Hosts Fiscal 2011 First Quarter Earnings Webcast 2Amarin Announces Successful Completion of Offering of American Depositary Shares 2Amarin Announces Successful Completion of Offering of American Depositary Shares 3
Microscissors : Horizontal Scissors...
Disposable Microscissors: Vertical, 90...
Microscissors: Eckardt Vertical Retinomy Scissors...
... the original and very popular ... for cutting in the vertical ... curved tips allow greater versatility ... retlna. Tip is shaped like ...
Medicine Products: